Beranda › Kelebihan Berat Badan › Kentucky
Uji klinis Kelebihan Berat Badan di Kentucky
21 studi untuk Kelebihan Berat Badan mencari peserta di lokasi di Kentucky.
Kota di Kentucky
Teks studi resmi (Bahasa Inggris)
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
- L-MARC Research Center /ID# 282008, Louisville
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT07752979Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
- AMR Clinical - Lexington, Lexington
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT07685808A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
- Monroe Biomedical Research - Louisville, Louisville
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07794579A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
- Monroe Biomedical Research, Louisville
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07595549A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- Norton Children's Endocrinology, Louisville
Menerima pesertaFase 3
Usia 6 hingga 17 · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06672549Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Gastroenterology Health Partners, Louisville
Menerima pesertaFase 3
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06937099Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Gastroenterology Health Partners, Louisville
Menerima pesertaFase 3
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06937086A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- AMR Clinical, Lexington
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07392190A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- Monroe Biomedical Research - Louisville, Louisville
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07589608Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
- Monroe Biomedical Research - Louisville, Louisville
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07353931A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- Monroe Biomedical Research, Louisville
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT07351045Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
- L-MARC Research Center, Louisville
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT07770841A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Monroe Biomedical Research - Louisville, Louisville
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT06143956A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
- The Alliance for Multispecialty Research LLC AMR, Lexington
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT07745504A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- Equity Medical - Bowling Green, Bowling Green
Menerima pesertaFase 4
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT06857942Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Monroe Biomedical Research, Louisville
Menerima pesertaFase 3
Usia 18 hingga 99 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT07684235AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
- Monroe Biomedical Research, LLC, Louisville
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT07509307Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Louisville
Menerima pesertaFase 3
Usia 18 hingga 79 · Semua jenis kelamin · Diperbarui 10 Agu 2026 · NCT07654361Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity
- University of Kentucky, Lexington
Menerima pesertaStudi observasional
Usia 12 hingga 17 · Semua jenis kelamin · Diperbarui 21 Jul 2026 · NCT06967389A Phase 2A Clinical Trial to Assess the Safety and Tolerability of ERX1000 in Men and Women for the Treatment of Obesity.
- Monroe Biomedical Research, Louisville
Menerima pesertaFase 2
Usia 18 hingga 60 · Semua jenis kelamin · Diperbarui 22 Jun 2026 · NCT07570758A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity
- MBX Biosciences Investigational Site, Lexington
Menerima pesertaFase 1
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 9 Jun 2026 · NCT07142707Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.